BioSilta Introduces EnPresso B Growth Systems for Bacterial Cultures
BioSilta Oy, a developer of advanced microbial growth systems, has announced the commercial launch of the first products in its proprietary EnPresso B range of reagent-based growth systems for bacterial cultures. Extensive results from independent labs around the world (available at www.biosilta.com) have confirmed that these new products typically increase protein yields by five to 100-fold and improve protein functionality when compared with results using conventional growth media.
The EnPresso B range has been developed in response to findings from market research involving more than 1200 scientists routinely growing bacterial cultures for the expression of recombinant proteins at laboratory scale. The majority of respondees highlighted insufficient yield, followed by quality problems such as poor protein solubility or low activity, as their main challenges.
The products are EnPresso B, EnPresso B Animal-free (supplied with documentation to certify that the product is free from animal-derived components), and EnPresso B Defined Nitrogen-free, used to significantly increase the yield of 15N-labeled proteins for NMR analysis.
For ease of use the products are supplied as presterilized tablets, which are simply added to sterile, filtered water. Optimized protocols enable researchers to go from pre-culture to harvest within 2 days, using standard lab equipment such as shake flasks or 24 deep well plates.
The EnPresso B range incorporates the Company’s patented EnBase technology that offers a novel approach to control the feeding, and thereby growth rate, of microbial cultures. A glucose-releasing agent breaks down long chains of polysaccharides, releasing glucose units to feed the microbes. As well as glucose, EnPresso tablets provide other key elements to support growth and control pH. Cells grow steadily to reach higher densities before induction of protein expression and continue in linear growth for many hours after induction. Proteins are expressed under optimal metabolic conditions thereby reducing the risk of incorrect folding and increasing the percentage of soluble protein. In contrast, microbes cultivated in conventional media grow in an uncontrolled manner, consuming nutrients, changing pH and depleting oxygen. Growth stops within hours, limiting protein yields and ‘too fast’ metabolism produces poor quality proteins.
Bob Penney, CEO, BioSilta Oy, said: “In our market research more than 70% of scientists confirmed that their main challenge when producing recombinant proteins in bacterial systems was insufficient yield, followed by problems with poor solubility and functionality. We firmly believe that EnPresso B growth systems very significantly address these issues and will revolutionize the role of bacterial cell culture in protein expression. Scientists will spend less time optimizing expression systems and more time focused on their true research objectives.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance